SYNGAP1 encephalopathy is a rare genetic disorder for which there is no treatment. It causes epilepsy, intellectual disability, psychomotor delay and, frequently, autism. It arises from mutations in ...
Ocugen's gene-agnostic therapy strategy targets broad retinal patient groups with one-time treatments, setting up major 2026-27 catalyst events.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association ...
New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly ...
Roswell Park researchers present a two-step, mechanism-based drug strategy at AACR 2026 that selectively targets cancers with ...
Researchers say a new AI system can identify disease-causing mutations and explain their biological effects, potentially ...
Rezetapopt demonstrated a 44.4% overall response rate and durable responses lasting over eight months in patients with ...
As the body ages, cells naturally accumulate dozens of genetic mutations each year. New research from Boston Children's ...
Triple-negative breast cancer (TNBC), particularly the luminal androgen receptor (LAR) subtype, presents significant ...
A new Nature study suggests DNA mutations in immune cells may drive autoimmune diseases by removing immune system brakes, ...
A newly identified COVID-19 variant is drawing attention from health officials after being detected in the U.S., though early evidence suggests it is not yet driving a surge in cases or severe illness ...
A man from Norway has likely been cured of HIV after receiving a stem cell transplant from his brother, who has two copies of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results